China: A recent secondary analysis of the CATIS-2 randomized clinical trial has revealed that early initiation of ...

Philips has now developed a device intended to integrate two forms of laser-based PAD therapy, atherectomy and intravascular ...

The most common cause of PAD is the buildup of plaque in blood vessels called "hardening" of the arteries. If you have hardening of the arteries in your legs, you most likely will have it in the ...

Philips announced the first U.S. treatment using its new laser device that combines two peripheral artery disease (PAD) procedures into one.

RT intensity was assessed according to the American College of Sports Medicine guidelines by 1 repetition maximum or rating of perceived ... Trials were also excluded if asymptomatic patients were ...

Despite an uptick in recent research associated with PAD diagnosis and treatment, 41.2% of clinical trial participants are women and 11% identify as Hispanic—creating a gap in evidence-based ...

The company has announced that its new investigational device exemption will be used to launch a pivotal trial of its ...

Endologix announced final 36-month results for the DETOUR2 study evaluating its Detour system for treating peripheral ...

[9] For these reasons, it has recently been proposed that L-propionyl carnitine (LPC) may be effective in the treatment of PAD, as LPC has been shown to improve the supply of metabolic substrates ...

Elsewhere in the market of PAD treatment, AngioDynamics has secured a European CE mark for the Auryon Atherectomy System, a laser technology used for the treatment of peripheral artery disease (PAD).